Gapping up
In reaction to strong earnings/guidance:
- VAPO +1.5%, NEO +1.4%, TSM +1.2%
Other news:
- CTSO +36.3% (FDA has granted Emergency Use Authorization (EUA) of CytoSorb for use in patients with COVID-19 infection)
- BCRX +35.7% (opens enrollment into a clinical trial to assess galidesivir in patients with COVID-19)
- PSTI +23.5% (cleared by FDA to proceed with the treatment in US under Coronavirus Treatment Acceleration Program)
- ATHX +16.5% (FDA authorizes athersys to initiate a pivotal clinical trial evaluating MultiStem cell therapy in patients with COVID-19 induced acute respiratory distress syndrome)
- RDHL +15.7% (Provides initial update from its Opaganib COVID-19 compassionate use program in israel)
- AMRS +11.3% (announces full market launch and sales of its Pipette branded hand sanitizer as of April 9)
- FENC +10.7% (FDA has accepted for filing and granted Priority Review for the company's New Drug Application (NDA) for PEDMARK)
- ALNY +7.1% (Blackstone (BX) will provide up to $2 billion to support Alnylam's advancement of innovative RNAi medicines)
- CEMI +6.3% (collaborates with Stony Brook Medicine to identify coronavirus survivors)
- MD +6.1% (provides COVID-19 update)
- ADRO +5.3% (details current status of clinical programs)
- REVG +4.8% (suspends dividend, furloughs employees)
- OMI +4.6% (discloses update relating to the pending divestiture of its Movianto business for $133 mln in cash)
- BHC +4.1% (initiates VIRAZOLE (Ribavirin for Inhalation Solution, USP) clinical study in patients with COVID-19)
- GILD +3.8% (data on 53 patients treated with investigational antiviral Remdesivir through the compassionate use program published in New England Journal of Medicine)
- VVNT +2.8% (provides COVID-19 business update)
- GD +2.7% (part of a group of companies that were awarded $5 bln US Army modifications)
Analyst comments:
- LPTH +3.8% (upgraded to Buy from Neutral at B. Riley FBR)
- DNKN +3.5% (upgraded to Outperform from Underperform at Credit Suisse)
- DDOG +1.5% (upgraded to Buy from Neutral at Goldman)
- ZS +1.5% (upgraded to Buy from Neutral at Rosenblatt)
- IPHI +1.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)